Dermatology News

Dermatology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Astorga BG et al. - Treatment with BCT shows an increase in RR, some achieving durable CR; nevertheless it cannot be considered a standard treatment and should be employed only in selected patients.

Related Articles

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy
The Oncologist, 10/30/09    Relevance Score: 70%

Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09    Relevance Score: 70%

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09    Relevance Score: 69%

Dormancy of metastatic melanoma
Pigment Cell & Melanoma Research, 11/11/09    Relevance Score: 68%

Metastatic cutaneous malignant melanoma: Spectrum of imaging findings and the role of multimodality imaging
Journal of Medical Imaging and Radiation Oncology (JMIRO), 10/05/09    Relevance Score: 68%

Today in Clinical Pharmacology...keeping you current

Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults
Journal of the European Academy of Dermatology and Venereology, 12/17/09

Multiple epidermal cysts occcurring in a tattoo
Singapore Medical Journal, 12/17/09

Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infection: a meta-analysis
Current Medical Research and Opinion, 12/17/09

Today in Dermatologic Oncology...keeping you current

Smoking, sun exposure, number of nevi and previous neoplasias are risk factors for melanoma in older patients (60 years and over)
Journal of the European Academy of Dermatology and Venereology, 12/17/09

Comparative genomic hybridization for the diagnosis of melanoma
European Journal of Plastic Surgery, 12/17/09

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center
Leukemia and Lymphoma, 12/17/09